The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Vaccine Market Research Report 2025
Synopsis
The global market for Human Vaccine was valued at US$ 34990 million in the year 2024 and is projected to reach a revised size of US$ 47870 million by 2031, growing at a CAGR of 4.6% during the forecast period.
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.
In China, Human Vaccine key players include CNBG, Kangtai, ChengDa Bio, etc. Global top three manufacturers hold a share about 65%.
East China is the largest market, with a share about 25%, followed by South China, and North China, both have a share about 40 percent.
In terms of product, Hepatitis B is the largest segment, with a share nearly 15%. And in terms of application, the largest application is Children, followed by Adults.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Vaccine.
The Human Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
CNBG
Changsheng Life
Zhifei
ChengDa Bio
Kangtai
SINOVAC BIOTECH
Hissen
Walvax Biotechnology
GSK
SANOFI
Rong An
NuoCheng Bio
Hualan Bio
Tiantan biological
Changchun Baike
Adimmune
Zhongyianke Biotech
Bharat Biotech
Bavarian Nordic
Sanofi-Pasteur
Indian Immunologicals
KANGH
Henan Grand Biopharma
ZhongKe Biopharm
Zhuoyi Biological
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Rota vaccine
Segment by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Human Vaccine was valued at US$ 34990 million in the year 2024 and is projected to reach a revised size of US$ 47870 million by 2031, growing at a CAGR of 4.6% during the forecast period.
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.
In China, Human Vaccine key players include CNBG, Kangtai, ChengDa Bio, etc. Global top three manufacturers hold a share about 65%.
East China is the largest market, with a share about 25%, followed by South China, and North China, both have a share about 40 percent.
In terms of product, Hepatitis B is the largest segment, with a share nearly 15%. And in terms of application, the largest application is Children, followed by Adults.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Vaccine.
The Human Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
CNBG
Changsheng Life
Zhifei
ChengDa Bio
Kangtai
SINOVAC BIOTECH
Hissen
Walvax Biotechnology
GSK
SANOFI
Rong An
NuoCheng Bio
Hualan Bio
Tiantan biological
Changchun Baike
Adimmune
Zhongyianke Biotech
Bharat Biotech
Bavarian Nordic
Sanofi-Pasteur
Indian Immunologicals
KANGH
Henan Grand Biopharma
ZhongKe Biopharm
Zhuoyi Biological
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Rota vaccine
Segment by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Human Vaccine Market Overview
1.1 Product Definition
1.2 Human Vaccine by Type
1.2.1 Global Human Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Polio
1.2.5 Hepatitis A
1.2.6 Rabies
1.2.7 BCG
1.2.8 Hepatitis B
1.2.9 Pertussis, Diphtheria, Tetanus
1.2.10 Pneumococcal
1.3 Human Vaccine by Application
1.3.1 Global Human Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Adults
1.3.3 Children
1.4 Global Human Vaccine Market Size Estimates and Forecasts
1.4.1 Global Human Vaccine Revenue 2020-2031
1.4.2 Global Human Vaccine Sales 2020-2031
1.4.3 Global Human Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Human Vaccine Market Competition by Manufacturers
2.1 Global Human Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Human Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Human Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Human Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Human Vaccine, Date of Enter into This Industry
2.8 Global Human Vaccine Market Competitive Situation and Trends
2.8.1 Global Human Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Human Vaccine Players Market Share by Revenue
2.8.3 Global Human Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Vaccine Market Scenario by Region
3.1 Global Human Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Human Vaccine Sales by Region: 2020-2031
3.2.1 Global Human Vaccine Sales by Region: 2020-2025
3.2.2 Global Human Vaccine Sales by Region: 2026-2031
3.3 Global Human Vaccine Revenue by Region: 2020-2031
3.3.1 Global Human Vaccine Revenue by Region: 2020-2025
3.3.2 Global Human Vaccine Revenue by Region: 2026-2031
3.4 North America Human Vaccine Market Facts & Figures by Country
3.4.1 North America Human Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Human Vaccine Sales by Country (2020-2031)
3.4.3 North America Human Vaccine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Vaccine Market Facts & Figures by Country
3.5.1 Europe Human Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Human Vaccine Sales by Country (2020-2031)
3.5.3 Europe Human Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Human Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Human Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Human Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Vaccine Market Facts & Figures by Country
3.7.1 Latin America Human Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Human Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Human Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Human Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Human Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Vaccine Sales by Type (2020-2031)
4.1.1 Global Human Vaccine Sales by Type (2020-2025)
4.1.2 Global Human Vaccine Sales by Type (2026-2031)
4.1.3 Global Human Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Human Vaccine Revenue by Type (2020-2031)
4.2.1 Global Human Vaccine Revenue by Type (2020-2025)
4.2.2 Global Human Vaccine Revenue by Type (2026-2031)
4.2.3 Global Human Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Human Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Human Vaccine Sales by Application (2020-2031)
5.1.1 Global Human Vaccine Sales by Application (2020-2025)
5.1.2 Global Human Vaccine Sales by Application (2026-2031)
5.1.3 Global Human Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Human Vaccine Revenue by Application (2020-2031)
5.2.1 Global Human Vaccine Revenue by Application (2020-2025)
5.2.2 Global Human Vaccine Revenue by Application (2026-2031)
5.2.3 Global Human Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Human Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 CNBG
6.1.1 CNBG Company Information
6.1.2 CNBG Description and Business Overview
6.1.3 CNBG Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 CNBG Human Vaccine Product Portfolio
6.1.5 CNBG Recent Developments/Updates
6.2 Changsheng Life
6.2.1 Changsheng Life Company Information
6.2.2 Changsheng Life Description and Business Overview
6.2.3 Changsheng Life Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Changsheng Life Human Vaccine Product Portfolio
6.2.5 Changsheng Life Recent Developments/Updates
6.3 Zhifei
6.3.1 Zhifei Company Information
6.3.2 Zhifei Description and Business Overview
6.3.3 Zhifei Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Zhifei Human Vaccine Product Portfolio
6.3.5 Zhifei Recent Developments/Updates
6.4 ChengDa Bio
6.4.1 ChengDa Bio Company Information
6.4.2 ChengDa Bio Description and Business Overview
6.4.3 ChengDa Bio Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 ChengDa Bio Human Vaccine Product Portfolio
6.4.5 ChengDa Bio Recent Developments/Updates
6.5 Kangtai
6.5.1 Kangtai Company Information
6.5.2 Kangtai Description and Business Overview
6.5.3 Kangtai Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Kangtai Human Vaccine Product Portfolio
6.5.5 Kangtai Recent Developments/Updates
6.6 SINOVAC BIOTECH
6.6.1 SINOVAC BIOTECH Company Information
6.6.2 SINOVAC BIOTECH Description and Business Overview
6.6.3 SINOVAC BIOTECH Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 SINOVAC BIOTECH Human Vaccine Product Portfolio
6.6.5 SINOVAC BIOTECH Recent Developments/Updates
6.7 Hissen
6.7.1 Hissen Company Information
6.7.2 Hissen Description and Business Overview
6.7.3 Hissen Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Hissen Human Vaccine Product Portfolio
6.7.5 Hissen Recent Developments/Updates
6.8 Walvax Biotechnology
6.8.1 Walvax Biotechnology Company Information
6.8.2 Walvax Biotechnology Description and Business Overview
6.8.3 Walvax Biotechnology Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Walvax Biotechnology Human Vaccine Product Portfolio
6.8.5 Walvax Biotechnology Recent Developments/Updates
6.9 GSK
6.9.1 GSK Company Information
6.9.2 GSK Description and Business Overview
6.9.3 GSK Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 GSK Human Vaccine Product Portfolio
6.9.5 GSK Recent Developments/Updates
6.10 SANOFI
6.10.1 SANOFI Company Information
6.10.2 SANOFI Description and Business Overview
6.10.3 SANOFI Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 SANOFI Human Vaccine Product Portfolio
6.10.5 SANOFI Recent Developments/Updates
6.11 Rong An
6.11.1 Rong An Company Information
6.11.2 Rong An Description and Business Overview
6.11.3 Rong An Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Rong An Human Vaccine Product Portfolio
6.11.5 Rong An Recent Developments/Updates
6.12 NuoCheng Bio
6.12.1 NuoCheng Bio Company Information
6.12.2 NuoCheng Bio Description and Business Overview
6.12.3 NuoCheng Bio Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 NuoCheng Bio Human Vaccine Product Portfolio
6.12.5 NuoCheng Bio Recent Developments/Updates
6.13 Hualan Bio
6.13.1 Hualan Bio Company Information
6.13.2 Hualan Bio Description and Business Overview
6.13.3 Hualan Bio Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Hualan Bio Human Vaccine Product Portfolio
6.13.5 Hualan Bio Recent Developments/Updates
6.14 Tiantan biological
6.14.1 Tiantan biological Company Information
6.14.2 Tiantan biological Description and Business Overview
6.14.3 Tiantan biological Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Tiantan biological Human Vaccine Product Portfolio
6.14.5 Tiantan biological Recent Developments/Updates
6.15 Changchun Baike
6.15.1 Changchun Baike Company Information
6.15.2 Changchun Baike Description and Business Overview
6.15.3 Changchun Baike Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Changchun Baike Human Vaccine Product Portfolio
6.15.5 Changchun Baike Recent Developments/Updates
6.16 Adimmune
6.16.1 Adimmune Company Information
6.16.2 Adimmune Description and Business Overview
6.16.3 Adimmune Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Adimmune Human Vaccine Product Portfolio
6.16.5 Adimmune Recent Developments/Updates
6.17 Zhongyianke Biotech
6.17.1 Zhongyianke Biotech Company Information
6.17.2 Zhongyianke Biotech Description and Business Overview
6.17.3 Zhongyianke Biotech Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Zhongyianke Biotech Human Vaccine Product Portfolio
6.17.5 Zhongyianke Biotech Recent Developments/Updates
6.18 Bharat Biotech
6.18.1 Bharat Biotech Company Information
6.18.2 Bharat Biotech Description and Business Overview
6.18.3 Bharat Biotech Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Bharat Biotech Human Vaccine Product Portfolio
6.18.5 Bharat Biotech Recent Developments/Updates
6.19 Bavarian Nordic
6.19.1 Bavarian Nordic Company Information
6.19.2 Bavarian Nordic Description and Business Overview
6.19.3 Bavarian Nordic Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Bavarian Nordic Human Vaccine Product Portfolio
6.19.5 Bavarian Nordic Recent Developments/Updates
6.20 Sanofi-Pasteur
6.20.1 Sanofi-Pasteur Company Information
6.20.2 Sanofi-Pasteur Description and Business Overview
6.20.3 Sanofi-Pasteur Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Sanofi-Pasteur Human Vaccine Product Portfolio
6.20.5 Sanofi-Pasteur Recent Developments/Updates
6.21 Indian Immunologicals
6.21.1 Indian Immunologicals Company Information
6.21.2 Indian Immunologicals Description and Business Overview
6.21.3 Indian Immunologicals Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Indian Immunologicals Human Vaccine Product Portfolio
6.21.5 Indian Immunologicals Recent Developments/Updates
6.22 KANGH
6.22.1 KANGH Company Information
6.22.2 KANGH Description and Business Overview
6.22.3 KANGH Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.22.4 KANGH Human Vaccine Product Portfolio
6.22.5 KANGH Recent Developments/Updates
6.23 Henan Grand Biopharma
6.23.1 Henan Grand Biopharma Company Information
6.23.2 Henan Grand Biopharma Description and Business Overview
6.23.3 Henan Grand Biopharma Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Henan Grand Biopharma Human Vaccine Product Portfolio
6.23.5 Henan Grand Biopharma Recent Developments/Updates
6.24 ZhongKe Biopharm
6.24.1 ZhongKe Biopharm Company Information
6.24.2 ZhongKe Biopharm Description and Business Overview
6.24.3 ZhongKe Biopharm Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.24.4 ZhongKe Biopharm Human Vaccine Product Portfolio
6.24.5 ZhongKe Biopharm Recent Developments/Updates
6.25 Zhuoyi Biological
6.25.1 Zhuoyi Biological Company Information
6.25.2 Zhuoyi Biological Description and Business Overview
6.25.3 Zhuoyi Biological Human Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.25.4 Zhuoyi Biological Human Vaccine Product Portfolio
6.25.5 Zhuoyi Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Vaccine Industry Chain Analysis
7.2 Human Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Vaccine Production Mode & Process Analysis
7.4 Human Vaccine Sales and Marketing
7.4.1 Human Vaccine Sales Channels
7.4.2 Human Vaccine Distributors
7.5 Human Vaccine Customer Analysis
8 Human Vaccine Market Dynamics
8.1 Human Vaccine Industry Trends
8.2 Human Vaccine Market Drivers
8.3 Human Vaccine Market Challenges
8.4 Human Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Human Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Human Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Human Vaccine Market Competitive Situation by Manufacturers in 2024
Table 4. Global Human Vaccine Sales (M Doses) of Key Manufacturers (2020-2025)
Table 5. Global Human Vaccine Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Human Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Human Vaccine Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Human Vaccine Average Price (USD/Dose) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Human Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Human Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Human Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Human Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Human Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Vaccine as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Human Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Human Vaccine Sales by Region (2020-2025) & (M Doses)
Table 18. Global Human Vaccine Sales Market Share by Region (2020-2025)
Table 19. Global Human Vaccine Sales by Region (2026-2031) & (M Doses)
Table 20. Global Human Vaccine Sales Market Share by Region (2026-2031)
Table 21. Global Human Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Human Vaccine Revenue Market Share by Region (2020-2025)
Table 23. Global Human Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Human Vaccine Revenue Market Share by Region (2026-2031)
Table 25. North America Human Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Human Vaccine Sales by Country (2020-2025) & (M Doses)
Table 27. North America Human Vaccine Sales by Country (2026-2031) & (M Doses)
Table 28. North America Human Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Human Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Human Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Human Vaccine Sales by Country (2020-2025) & (M Doses)
Table 32. Europe Human Vaccine Sales by Country (2026-2031) & (M Doses)
Table 33. Europe Human Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Human Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Human Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Human Vaccine Sales by Region (2020-2025) & (M Doses)
Table 37. Asia Pacific Human Vaccine Sales by Region (2026-2031) & (M Doses)
Table 38. Asia Pacific Human Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Human Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Human Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Human Vaccine Sales by Country (2020-2025) & (M Doses)
Table 42. Latin America Human Vaccine Sales by Country (2026-2031) & (M Doses)
Table 43. Latin America Human Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Human Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Human Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Human Vaccine Sales by Country (2020-2025) & (M Doses)
Table 47. Middle East and Africa Human Vaccine Sales by Country (2026-2031) & (M Doses)
Table 48. Middle East and Africa Human Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Human Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Human Vaccine Sales (M Doses) by Type (2020-2025)
Table 51. Global Human Vaccine Sales (M Doses) by Type (2026-2031)
Table 52. Global Human Vaccine Sales Market Share by Type (2020-2025)
Table 53. Global Human Vaccine Sales Market Share by Type (2026-2031)
Table 54. Global Human Vaccine Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Human Vaccine Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Human Vaccine Revenue Market Share by Type (2020-2025)
Table 57. Global Human Vaccine Revenue Market Share by Type (2026-2031)
Table 58. Global Human Vaccine Price (USD/Dose) by Type (2020-2025)
Table 59. Global Human Vaccine Price (USD/Dose) by Type (2026-2031)
Table 60. Global Human Vaccine Sales (M Doses) by Application (2020-2025)
Table 61. Global Human Vaccine Sales (M Doses) by Application (2026-2031)
Table 62. Global Human Vaccine Sales Market Share by Application (2020-2025)
Table 63. Global Human Vaccine Sales Market Share by Application (2026-2031)
Table 64. Global Human Vaccine Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Human Vaccine Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Human Vaccine Revenue Market Share by Application (2020-2025)
Table 67. Global Human Vaccine Revenue Market Share by Application (2026-2031)
Table 68. Global Human Vaccine Price (USD/Dose) by Application (2020-2025)
Table 69. Global Human Vaccine Price (USD/Dose) by Application (2026-2031)
Table 70. CNBG Company Information
Table 71. CNBG Description and Business Overview
Table 72. CNBG Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 73. CNBG Human Vaccine Product
Table 74. CNBG Recent Developments/Updates
Table 75. Changsheng Life Company Information
Table 76. Changsheng Life Description and Business Overview
Table 77. Changsheng Life Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 78. Changsheng Life Human Vaccine Product
Table 79. Changsheng Life Recent Developments/Updates
Table 80. Zhifei Company Information
Table 81. Zhifei Description and Business Overview
Table 82. Zhifei Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 83. Zhifei Human Vaccine Product
Table 84. Zhifei Recent Developments/Updates
Table 85. ChengDa Bio Company Information
Table 86. ChengDa Bio Description and Business Overview
Table 87. ChengDa Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 88. ChengDa Bio Human Vaccine Product
Table 89. ChengDa Bio Recent Developments/Updates
Table 90. Kangtai Company Information
Table 91. Kangtai Description and Business Overview
Table 92. Kangtai Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 93. Kangtai Human Vaccine Product
Table 94. Kangtai Recent Developments/Updates
Table 95. SINOVAC BIOTECH Company Information
Table 96. SINOVAC BIOTECH Description and Business Overview
Table 97. SINOVAC BIOTECH Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 98. SINOVAC BIOTECH Human Vaccine Product
Table 99. SINOVAC BIOTECH Recent Developments/Updates
Table 100. Hissen Company Information
Table 101. Hissen Description and Business Overview
Table 102. Hissen Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 103. Hissen Human Vaccine Product
Table 104. Hissen Recent Developments/Updates
Table 105. Walvax Biotechnology Company Information
Table 106. Walvax Biotechnology Description and Business Overview
Table 107. Walvax Biotechnology Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 108. Walvax Biotechnology Human Vaccine Product
Table 109. Walvax Biotechnology Recent Developments/Updates
Table 110. GSK Company Information
Table 111. GSK Description and Business Overview
Table 112. GSK Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 113. GSK Human Vaccine Product
Table 114. GSK Recent Developments/Updates
Table 115. SANOFI Company Information
Table 116. SANOFI Description and Business Overview
Table 117. SANOFI Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 118. SANOFI Human Vaccine Product
Table 119. SANOFI Recent Developments/Updates
Table 120. Rong An Company Information
Table 121. Rong An Description and Business Overview
Table 122. Rong An Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 123. Rong An Human Vaccine Product
Table 124. Rong An Recent Developments/Updates
Table 125. NuoCheng Bio Company Information
Table 126. NuoCheng Bio Description and Business Overview
Table 127. NuoCheng Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 128. NuoCheng Bio Human Vaccine Product
Table 129. NuoCheng Bio Recent Developments/Updates
Table 130. Hualan Bio Company Information
Table 131. Hualan Bio Description and Business Overview
Table 132. Hualan Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 133. Hualan Bio Human Vaccine Product
Table 134. Hualan Bio Recent Developments/Updates
Table 135. Tiantan biological Company Information
Table 136. Tiantan biological Description and Business Overview
Table 137. Tiantan biological Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 138. Tiantan biological Human Vaccine Product
Table 139. Tiantan biological Recent Developments/Updates
Table 140. Changchun Baike Company Information
Table 141. Changchun Baike Description and Business Overview
Table 142. Changchun Baike Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 143. Changchun Baike Human Vaccine Product
Table 144. Changchun Baike Recent Developments/Updates
Table 145. Adimmune Company Information
Table 146. Adimmune Description and Business Overview
Table 147. Adimmune Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 148. Adimmune Human Vaccine Product
Table 149. Adimmune Recent Developments/Updates
Table 150. Zhongyianke Biotech Company Information
Table 151. Zhongyianke Biotech Description and Business Overview
Table 152. Zhongyianke Biotech Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 153. Zhongyianke Biotech Human Vaccine Product
Table 154. Zhongyianke Biotech Recent Developments/Updates
Table 155. Bharat Biotech Company Information
Table 156. Bharat Biotech Description and Business Overview
Table 157. Bharat Biotech Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 158. Bharat Biotech Human Vaccine Product
Table 159. Bharat Biotech Recent Developments/Updates
Table 160. Bavarian Nordic Company Information
Table 161. Bavarian Nordic Description and Business Overview
Table 162. Bavarian Nordic Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 163. Bavarian Nordic Human Vaccine Product
Table 164. Bavarian Nordic Recent Developments/Updates
Table 165. Sanofi-Pasteur Company Information
Table 166. Sanofi-Pasteur Description and Business Overview
Table 167. Sanofi-Pasteur Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 168. Sanofi-Pasteur Human Vaccine Product
Table 169. Sanofi-Pasteur Recent Developments/Updates
Table 170. Indian Immunologicals Company Information
Table 171. Indian Immunologicals Description and Business Overview
Table 172. Indian Immunologicals Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 173. Indian Immunologicals Human Vaccine Product
Table 174. Indian Immunologicals Recent Developments/Updates
Table 175. KANGH Company Information
Table 176. KANGH Description and Business Overview
Table 177. KANGH Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 178. KANGH Human Vaccine Product
Table 179. KANGH Recent Developments/Updates
Table 180. Henan Grand Biopharma Company Information
Table 181. Henan Grand Biopharma Description and Business Overview
Table 182. Henan Grand Biopharma Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 183. Henan Grand Biopharma Human Vaccine Product
Table 184. Henan Grand Biopharma Recent Developments/Updates
Table 185. ZhongKe Biopharm Company Information
Table 186. ZhongKe Biopharm Description and Business Overview
Table 187. ZhongKe Biopharm Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 188. ZhongKe Biopharm Human Vaccine Product
Table 189. ZhongKe Biopharm Recent Developments/Updates
Table 190. Zhuoyi Biological Company Information
Table 191. Zhuoyi Biological Description and Business Overview
Table 192. Zhuoyi Biological Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 193. Zhuoyi Biological Human Vaccine Product
Table 194. Zhuoyi Biological Recent Developments/Updates
Table 195. Key Raw Materials Lists
Table 196. Raw Materials Key Suppliers Lists
Table 197. Human Vaccine Distributors List
Table 198. Human Vaccine Customers List
Table 199. Human Vaccine Market Trends
Table 200. Human Vaccine Market Drivers
Table 201. Human Vaccine Market Challenges
Table 202. Human Vaccine Market Restraints
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
Table 206. Authors List of This Report
List of Figures
Figure 1. Product Picture of Human Vaccine
Figure 2. Global Human Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Human Vaccine Market Share by Type: 2024 & 2031
Figure 4. Varicella Product Picture
Figure 5. Influenza Product Picture
Figure 6. Polio Product Picture
Figure 7. Hepatitis A Product Picture
Figure 8. Rabies Product Picture
Figure 9. BCG Product Picture
Figure 10. Hepatitis B Product Picture
Figure 11. Pertussis, Diphtheria, Tetanus Product Picture
Figure 12. Pneumococcal Product Picture
Figure 13. Global Human Vaccine Market Value by Application (2020-2031) & (US$ Million)
Figure 14. Global Human Vaccine Market Share by Application: 2024 & 2031
Figure 15. Adults
Figure 16. Children
Figure 17. Global Human Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Human Vaccine Market Size (2020-2031) & (US$ Million)
Figure 19. Global Human Vaccine Sales (2020-2031) & (M Doses)
Figure 20. Global Human Vaccine Average Price (USD/Dose) & (2020-2031)
Figure 21. Human Vaccine Report Years Considered
Figure 22. Human Vaccine Sales Share by Manufacturers in 2024
Figure 23. Global Human Vaccine Revenue Share by Manufacturers in 2024
Figure 24. Global 5 and 10 Largest Human Vaccine Players: Market Share by Revenue in Human Vaccine in 2024
Figure 25. Human Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 26. Global Human Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 27. North America Human Vaccine Sales Market Share by Country (2020-2031)
Figure 28. North America Human Vaccine Revenue Market Share by Country (2020-2031)
Figure 29. U.S. Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Canada Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Europe Human Vaccine Sales Market Share by Country (2020-2031)
Figure 32. Europe Human Vaccine Revenue Market Share by Country (2020-2031)
Figure 33. Germany Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. France Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. U.K. Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Italy Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Russia Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Asia Pacific Human Vaccine Sales Market Share by Region (2020-2031)
Figure 39. Asia Pacific Human Vaccine Revenue Market Share by Region (2020-2031)
Figure 40. China Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Japan Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. South Korea Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. India Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Australia Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Taiwan Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Indonesia Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Thailand Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Malaysia Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Philippines Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Latin America Human Vaccine Sales Market Share by Country (2020-2031)
Figure 51. Latin America Human Vaccine Revenue Market Share by Country (2020-2031)
Figure 52. Mexico Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Brazil Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Argentina Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Middle East and Africa Human Vaccine Sales Market Share by Country (2020-2031)
Figure 56. Middle East and Africa Human Vaccine Revenue Market Share by Country (2020-2031)
Figure 57. Turkey Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Saudi Arabia Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. U.A.E Human Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 60. Global Sales Market Share of Human Vaccine by Type (2020-2031)
Figure 61. Global Revenue Market Share of Human Vaccine by Type (2020-2031)
Figure 62. Global Human Vaccine Price (USD/Dose) by Type (2020-2031)
Figure 63. Global Sales Market Share of Human Vaccine by Application (2020-2031)
Figure 64. Global Revenue Market Share of Human Vaccine by Application (2020-2031)
Figure 65. Global Human Vaccine Price (USD/Dose) by Application (2020-2031)
Figure 66. Human Vaccine Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
